These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950 [Abstract] [Full Text] [Related]
14. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D'Agostino A, Faiola V, Addeo R. Cancer Chemother Pharmacol; 2010 Oct; 66(5):837-44. PubMed ID: 20041325 [Abstract] [Full Text] [Related]
15. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Barbare JC, Bouché O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP, Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, Bedenne L. Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768 [Abstract] [Full Text] [Related]
20. [Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy]. Hirashita T, Nakashima K, Sakai M, Sakai I. Gan To Kagaku Ryoho; 2007 Jul; 34(7):1123-6. PubMed ID: 17637554 [Abstract] [Full Text] [Related] Page: [Next] [New Search]